Washington (AFP)
Novavax said Monday that its anti-Covid vaccine was more than 90% effective, including against variants, after a study carried out on nearly 30,000 people in the United States and Mexico.
The vaccine "showed 100% protection against moderate and severe forms of the disease and 90.4% overall," said the US biotech company in a statement, adding that it intended to seek official authorization for marketed by the end of the third quarter of 2021.
Novavax estimates that it will then be able to produce one hundred million doses per month, then one hundred and fifty million by the end of the year.
"Novavax has moved closer to its goal of meeting the persistent and critical global public health demand for new anti-Covid vaccines," said Stanley Erck, president of the company.
Novavax's vaccine - NVX-CoV2373 in the official terminology - uses a different technology from those used for vaccines already widely authorized in the world: it is a so-called "subunit" vaccine, based on proteins that trigger a response. immune, virus-free.
Unlike other vaccines, it does not need to be stored at very cold temperatures, but only between 2 and 8 ° C, which could make it easier to transport and administer in the most vulnerable countries. less developed.
More than two billion doses of Covid-19 vaccines have been administered worldwide, but inequalities are very strong between nations.
The richest countries promised Friday a billion doses of anti-Covid vaccines to the poorest at the G7 Summit.
© 2021 AFP